MiNK Therapeutics Stock (NASDAQ:INKT)
Previous Close
$7.88
52W Range
$4.56 - $13.79
50D Avg
$8.97
200D Avg
$8.08
Market Cap
$33.00M
Avg Vol (3M)
$30.12K
Beta
0.14
Div Yield
-
INKT Company Profile
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
INKT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ALVR | AlloVir, Inc. |
| AFMD | Affimed N.V. |
| TERN | Terns Pharmaceuticals, Inc. |
| ADAP | Adaptimmune Therapeutics plc |
| SGMO | Sangamo Therapeutics, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| CADL | Candel Therapeutics, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| HOWL | Werewolf Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| IKNA | Ikena Oncology, Inc. |
| INZY | Inozyme Pharma, Inc. |
| FBRX | Forte Biosciences, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |